ロード中...
Binimetinib (MEK162) in recurrent low-grade serous ovarian cancer resistant to chemotherapy and hormonal treatment
BACKGROUND: Management of advanced/recurrent low-grade serous ovarian carcinoma (LGOSC) is often challenging. Effective treatment options remain limited for hormone and chemotherapy-resistant LGSOC. CASE: A 65-year-old woman with recurrent widespread LGSOC harboring the KRAS-G12 V hotspot mutation e...
保存先:
| 出版年: | Gynecol Oncol Rep |
|---|---|
| 主要な著者: | , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Elsevier
2018
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6014583/ https://ncbi.nlm.nih.gov/pubmed/29946554 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.gore.2018.05.011 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|